Loading data for BHVN — first visit, this takes a few seconds.

Alerta

Biohaven Ltd. (BHVN)

: BHVN · Precio en tiempo real · USD

n/a

n/a (n/a)

Al cierre: Invalid Date

14.12

+1.95%

Fuera de horario: 7:56 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	n/a
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-586.84M
	3.16
	n/a
	n/a
	-6.97
P/B (TTM)	170.99
P/S (TTM)	n/a
Fecha de resultados	Nov 9, 2026

Precio de venta	n/a
Volumen	NaN
Volumen medio (20D)	n/a
Abierto	n/a
Anterior Cerrar	n/a
Rango del día	n/a - n/a
Rango de 52 semanas	n/a - n/a
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de BHVN

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum c...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Sep 23, 2022

Empleados 274

Bolsa de Valores NYSE

Símbolo bursátil BHVN

Sitio web https://www.biohaven.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Biohaven fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -738.82M, una disminución de -12.71%.

Estados financieros

Sorpresa de resultados

Biohaven ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
EPS de -0.78 falla las estimaciones por -0.17, con 52.15% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Biohaven Ltd. publique sus resultados el Nov 9, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 días hace · Simply Wall St.

Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News

Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With...

1 semana hace · Insider Monkey

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a c...

3 semanas hace · MT Newswires

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged

1 mes hace · BioPharma Dive

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

1 mes hace · Simply Wall St.

Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?

Biohaven announced a series of scientific leadership changes, including the upcoming transition of Bruce Car, Ph.D., to Chief Innovation Officer, the promotion of David Pirman, Ph.D., to Executive Vic...

Página 1 de 2

Biohaven Ltd. (BHVN)